Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 35, Issue SUPPL. 4, 2002, Pages

  Tolia, Vasundhara ^a   Fitzgerald, Joseph ^b   Hassall, Eric ^c   Huang, Bidan ^d   Pilmer, Betsy ^e   Kane III, Robert ^f  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

^c BC CHILDREN S HOSPITAL   (Canada)

^d ABBOTT LABORATORIES   (United States)

^e TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^f Cardinal Glennon Hospital   (United States)

Author keywords

Adolescents; Adverse events; Children; Gastrin; Gastroesophageal reflux disease; Lansoprazole; Safety

Indexed keywords

DIGOXIN; GASTRIN; LANSOPRAZOLE; PHENYTOIN;

ABDOMINAL PAIN; ARTICLE; ASPIRATION PNEUMONIA; ASTHMA; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS PH; FEMALE; GASTRIN BLOOD LEVEL; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HUMAN; HYPOVENTILATION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PH MEASUREMENT; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; VOMITING;

EID: 0036447317     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200211004-00002     Document Type: Article

References (27)

1. Callahan CW. The diagnosis of gastroesophageal reflux in hospitalized infants: 1971-1995. J Am Osteopath Assoc 1998;98:32-4.
2. Tolia V. Indications for proton pump inhibitors in pediatrics. Paediatrics Today 2001;IV:180-6.
3. Kane RE, Sarr M, Foy TM. Omeprazole versus lansoprazole in the treatment of children with peptic esophagitis refractory to H2 antagonists [abstract]. Gastroenterology 1997;112(suppl 4):A166.
4. Oderda G, Chiorboli E, Rapa A, Haitink O, Bona G. Inhibition of gastric acidity in children by lansoprazole in granules [abstract]. Gastroenterology 1998;114:A245.
5. Cucchiara S, Borrelli O, Gaudiello G, et al. Lansoprazole in children with severe gastroesophageal reflux disease: Effect on gastric acidity, esophagitis and clinical outcome [abstract]. Gastroenterology 1999;116:A142.
6. Franco MT, Salvia G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000;32:660-6.
7. Faure C, Michaud L, Shaghaghi EK, et al. Lansoprazole in children: Pharmacokinetics and efficacy in reflux oesophagitis. Aliment Pharmacol Ther 2001;15:1397-402.
8. Abdullah B, Gupta SK, Fitzgerald JF, Chong SKF, Croffie JM. Long-term management of moderate/severe peptic esophagitis in children/adolescents. H2 blocker vs. proton pump inhibitor (PPI) [abstract]. Gastroenterology 1998;114:A51.
9. Gunasekaran TS, Hassall E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993;123:148-54.
10. Malone T, Kuczmanski M, Levine D, Gold B, Gunasekaran T. Omeprazole safely and effectively relieved symptoms of GERD in a pediatric population aged 2-16 years [abstract]. J Pediatr Gastroenterol Nutr 2001;33:423.
11. Colletti RB, Hassall E, Heyman MB, Winter HS. Use of proton pump inhibitors (PPIs) by pediatric gastroenterologists [abstract]. J Pediatr Gastroenterol Nutr 2001;33:414.
12. Kato S, Ebina K, Fojii K, et al. Effect of omeprazole in the treatment of refractory acid related disease in childhood: Endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996; 128:415-21.
13. Gremse D, Witner H, Tolia V, Gunasekaran T, Pan W-J, Karol M, Chiu Y-L, et al. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatric Gastroenterol Nutr 2002;35(suppl 4):S319-26.
14. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (suppl 4):S308-18.
15. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. Am J Gastroenterol 1974;62:325-32.
16. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of lansoprazole: The US clinical trial experience. Drug Safety 1999;20:195-205.
17. Hassall E, Israel D, Shepherd R, Radke M, et al. Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. J Pecliatr 2000;137:800-7.
18. Hendriks HG, van Kreel B, Forget PP. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients. J Pediatr Gastroenterol Nutr 2001;33:260-5.
19. Freston JW. Long-term acid control and proton pump inhibitors: Interaction and safety issues in perspective. Am J Gastroenterol 1997;92:51S-7S.
20. Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990;19:141-53.
21. Havu N, Mattsson H, Carlsson K, Lundell L, Carlsson E, Brautigam J. Partial fundectomy results in hypergastrinemia and the development of gastric ECL cell carcinoids in the rat [abstract]. Scand J Gastroenterol 1989;24(Suppl 166):158.
22. Mattsson H, Havu N, Brautigam J, Carlsson K, Lundell L, Carlsson E. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffin-like cell carcinoids in the rat. Gastroenterol 1991;100:311-9.
23. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterol 2000; 118:661-9.
24. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM, and the Lansoprazole Group. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996;91:1749-57.
25. Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: Pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998;27:568-79.
26. Spencer CM, Faulds D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-30.
27. Sachs G. The safety of omeprazole: True or false. Gastroenterology 1994;106:1400-1.